Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer

Kenta Furukawa, Koichi Kawamoto, Hidetoshi Eguchi, Masahiro Tanemura, Tsukasa Tanida, Yoshito Tomimaru, Hirofumi Akita, Naoki Hama, Hiroshi Wada, Shogo Kobayashi, Yuji Nonaka, Shinji Takamatsu, Shinichiro Shinzaki, Takashi Kumada, Shinji Satomura, Toshifumi Ito, Satoshi Serada, Tetsuji Naka, Masaki Mori, Yuichiro DokiEiji Miyoshi, Hiroaki Nagano

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Objectives: Leucine-rich α2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer. Methods: A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues. Results: Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signalwas scarcely detected in tissues from CP patients or normal surrounding tissue. Conclusions: These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.

Original languageEnglish
Pages (from-to)93-98
Number of pages6
JournalPancreas
Volume44
Issue number1
DOIs
Publication statusPublished - Jan 1 2015
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Leucine
Glycoproteins
Serum
Chronic Pancreatitis
Healthy Volunteers
Biomarkers
Tumor Biomarkers
Area Under Curve
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Carbohydrates
Staining and Labeling
Carcinoma
Antigens

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Furukawa, K., Kawamoto, K., Eguchi, H., Tanemura, M., Tanida, T., Tomimaru, Y., ... Nagano, H. (2015). Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer. Pancreas, 44(1), 93-98. https://doi.org/10.1097/MPA.0000000000000205

Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer. / Furukawa, Kenta; Kawamoto, Koichi; Eguchi, Hidetoshi; Tanemura, Masahiro; Tanida, Tsukasa; Tomimaru, Yoshito; Akita, Hirofumi; Hama, Naoki; Wada, Hiroshi; Kobayashi, Shogo; Nonaka, Yuji; Takamatsu, Shinji; Shinzaki, Shinichiro; Kumada, Takashi; Satomura, Shinji; Ito, Toshifumi; Serada, Satoshi; Naka, Tetsuji; Mori, Masaki; Doki, Yuichiro; Miyoshi, Eiji; Nagano, Hiroaki.

In: Pancreas, Vol. 44, No. 1, 01.01.2015, p. 93-98.

Research output: Contribution to journalArticle

Furukawa, K, Kawamoto, K, Eguchi, H, Tanemura, M, Tanida, T, Tomimaru, Y, Akita, H, Hama, N, Wada, H, Kobayashi, S, Nonaka, Y, Takamatsu, S, Shinzaki, S, Kumada, T, Satomura, S, Ito, T, Serada, S, Naka, T, Mori, M, Doki, Y, Miyoshi, E & Nagano, H 2015, 'Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer', Pancreas, vol. 44, no. 1, pp. 93-98. https://doi.org/10.1097/MPA.0000000000000205
Furukawa, Kenta ; Kawamoto, Koichi ; Eguchi, Hidetoshi ; Tanemura, Masahiro ; Tanida, Tsukasa ; Tomimaru, Yoshito ; Akita, Hirofumi ; Hama, Naoki ; Wada, Hiroshi ; Kobayashi, Shogo ; Nonaka, Yuji ; Takamatsu, Shinji ; Shinzaki, Shinichiro ; Kumada, Takashi ; Satomura, Shinji ; Ito, Toshifumi ; Serada, Satoshi ; Naka, Tetsuji ; Mori, Masaki ; Doki, Yuichiro ; Miyoshi, Eiji ; Nagano, Hiroaki. / Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer. In: Pancreas. 2015 ; Vol. 44, No. 1. pp. 93-98.
@article{45a18d9699b14bb883180a18ff69a257,
title = "Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer",
abstract = "Objectives: Leucine-rich α2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer. Methods: A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues. Results: Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signalwas scarcely detected in tissues from CP patients or normal surrounding tissue. Conclusions: These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.",
author = "Kenta Furukawa and Koichi Kawamoto and Hidetoshi Eguchi and Masahiro Tanemura and Tsukasa Tanida and Yoshito Tomimaru and Hirofumi Akita and Naoki Hama and Hiroshi Wada and Shogo Kobayashi and Yuji Nonaka and Shinji Takamatsu and Shinichiro Shinzaki and Takashi Kumada and Shinji Satomura and Toshifumi Ito and Satoshi Serada and Tetsuji Naka and Masaki Mori and Yuichiro Doki and Eiji Miyoshi and Hiroaki Nagano",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/MPA.0000000000000205",
language = "English",
volume = "44",
pages = "93--98",
journal = "Pancreas",
issn = "0885-3177",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Clinicopathological significance of leucine-rich α2-glycoprotein-1 in sera of patients with pancreatic cancer

AU - Furukawa, Kenta

AU - Kawamoto, Koichi

AU - Eguchi, Hidetoshi

AU - Tanemura, Masahiro

AU - Tanida, Tsukasa

AU - Tomimaru, Yoshito

AU - Akita, Hirofumi

AU - Hama, Naoki

AU - Wada, Hiroshi

AU - Kobayashi, Shogo

AU - Nonaka, Yuji

AU - Takamatsu, Shinji

AU - Shinzaki, Shinichiro

AU - Kumada, Takashi

AU - Satomura, Shinji

AU - Ito, Toshifumi

AU - Serada, Satoshi

AU - Naka, Tetsuji

AU - Mori, Masaki

AU - Doki, Yuichiro

AU - Miyoshi, Eiji

AU - Nagano, Hiroaki

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives: Leucine-rich α2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer. Methods: A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues. Results: Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signalwas scarcely detected in tissues from CP patients or normal surrounding tissue. Conclusions: These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.

AB - Objectives: Leucine-rich α2-glycoprotein-1 (LRG-1) is an inflammatory protein. Serum LRG-1 levels can reportedly be used as a cancer biomarker for several types of carcinoma. In the present study, we investigated the clinical usefulness of serum LRG-1 levels as a biomarker of pancreatic cancer. Methods: A total of 124 patients with pancreatic cancer, 35 patients with chronic pancreatitis (CP), and 144 healthy volunteers were enrolled in the study. Serum LRG-1 levels were assayed by enzyme-linked immunosorbent assay. Immunohistochemistry was used to examine LRG-1 expression in pancreatic cancer tissues. Results: Serum LRG-1 levels were significantly increased in patients with pancreatic cancer compared with CP patients and healthy volunteers. The LRG-1 levels increased with progressive clinical stages of pancreatic cancer. Receiver operator curve analysis showed that a combination of carbohydrate antigen 19-9 and LRG-1 resulted in a higher area under the curve for the diagnosis of pancreatic cancer. Positive staining was observed in all cases of pancreatic cancer, but positive signalwas scarcely detected in tissues from CP patients or normal surrounding tissue. Conclusions: These results suggest that serum LRG-1 is a promising biomarker for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84919459079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919459079&partnerID=8YFLogxK

U2 - 10.1097/MPA.0000000000000205

DO - 10.1097/MPA.0000000000000205

M3 - Article

C2 - 25058884

AN - SCOPUS:84919459079

VL - 44

SP - 93

EP - 98

JO - Pancreas

JF - Pancreas

SN - 0885-3177

IS - 1

ER -